Advancing human epidermal growth factor receptor 2-positive gastric cancer therapy: Toward targeted immunotherapy and antibody-drug conjugates

doi:10.4251/wjgo.v18.i5.116882

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 5

This Article

(31)

(30)

(0)

(43)

(724)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. May 15, 2026; 18(5): 116882
Published online May 15, 2026. doi: 10.4251/wjgo.v18.i5.116882

Full Size Figure Download Figure

Figure 3 A precision diagnostic and therapeutic roadmap for human epidermal growth factor receptor 2-positive gastric cancer. This flowchart delineates the integrated clinical decision-making pathway, from initial diagnosis and molecular subtyping through the sequential selection of therapies (first- to later-line) and ongoing dynamic monitoring. NGS: Next-generation sequencing; ctDNA: Circulating tumor DNA; HER2: Human epidermal growth factor receptor 2; MET: Mesenchymal-epithelial transition factor; EGFR: Epidermal growth factor receptor; IO: Immunotherapy; ADC: Antibody-drug conjugate.

Citation: Xu JJ, Ni CX, Wang P, Qin LD, Xu JJ. Advancing human epidermal growth factor receptor 2-positive gastric cancer therapy: Toward targeted immunotherapy and antibody-drug conjugates. World J Gastrointest Oncol 2026; 18(5): 116882
URL: https://www.wjgnet.com/1948-5204/full/v18/i5/116882.htm
DOI: https://dx.doi.org/10.4251/wjgo.v18.i5.116882

Xu JJ, Ni CX, Wang P, Qin LD, Xu JJ. Advancing human epidermal growth factor receptor 2-positive gastric cancer therapy: Toward targeted immunotherapy and antibody-drug conjugates. World J Gastrointest Oncol 2026; 18(5): 116882 [DOI: 10.4251/wjgo.v18.i5.116882]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.